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INTRODUCTION
Among gynecologic cancers, epithelial ovarian cancer (EOC) 
is second only to cervical cancer in incidence and number of 
deaths caused [1]. Patients with ovarian cancer are staged accor­
ding to the International Federation of Obstetrics and Gyne­
cology (FIGO) system [2], which determines patient ma  na  ge­
ment and provides prognostic information (five­year survival 
rates are 32.5% and 18.6% for stages IIIC and IV, respectively) 
[3]. Cytoreductive surgery is the treatment of cho  ice for patients 
with ovarian cancer. “Optimal” cytoreductive surgery (residual 
disease <1 cm) is a very strong predictor of survival [4], and even af­
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Objective: To determine which computed tomography (CT) imaging features predict pleural malignancy in patients with advanced 
epithelial ovarian carcinoma (EOC) using video­assisted thoracic surgery (VATS), pathology, and cytology findings as the reference 
standard.
Methods: This retrospective study included 44 patients with International Federation of Obstetrics and Gynecology (FIGO) stage III 
or IV primary or recurrent EOC who had chest CT ≤30 days before VATS. Two radiologists independently reviewed the CT studies and 
recorded the presence and size of pleural effusions and of ascites; pleural nodules, thickening, enhancement, subdiaphragmatic 
tumour deposits and supradiaphragmatic, mediastinal, hilar, and retroperitoneal adenopathy; and peritoneal seeding. VATS, 
pathology, and cytology findings constituted the reference standard.
Results: In 26/44 (59%) patients, pleural biopsies were malignant. Only the size of left­sided pleural effusion (reader 1: rho= 
-0.39, p=0.01; reader 2: rho=-0.37, p=0.01) and presence of ascites (reader 1: rho=-0.33, p=0.03; reader 2: rho=-0.35, p=0.03) 
were significantly associated with solid pleural metastasis. Pleural fluid cytology was malignant in 26/35 (74%) patients. Only 
the presence (p=0.03 for both readers) and size (reader 1: rho=0.34, p=0.04; reader 2: rho=0.33, p=0.06) of right­sided pleural 
effusion were associated with malignant pleural effusion. Interobserver agreement was substantial (kappa=0.78) for effusion 
size and moderate (kappa=0.46) for presence of solid pleural disease. No other CT features were associated with malignancy at 
biopsy or cytology.
Conclusion: In patients with advanced EOC, ascites and left­sided pleural effusion size were associated with solid pleural meta­
stasis, while the presence and size of right­sided effusion were associated with malignant pleural effusion. No other CT features 
evaluated were associated with pleural malignancy.
Keywords: Computed tomography, Malignant/diagnosis, Ovarian neoplasms, Pleural effusion, Pleural neoplasms, Thoracic surgery/ 
video­assisted
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ter the threshold for optimal cytoreduction has been reached, 
it is important to remove as much of the residual tumor as 
possible [5]. 
Circulation of peritoneal fluid throughout the abdomen and 
pelvis commonly results in diaphragmatic tumor implants, and in 
turn, peritoneal­pleural communication through the diaphragm 
may allow trans­diaphragmatic spread of tumor into the tho­
rax [6]. Malignant thoracic involvement indicates FIGO stage 
IV disease, for which treatment options include neoadjuvant 
chemotherapy and, in patients who are candidates for optimal 
abdominal cytoreduction, thoracic debulking [7,8]. Neoadju­
vant chemotherapy followed by interval debulking surgery is 
a suitable alternative [9,10] that is supported by the outcome 
of a recent multicentre randomised controlled trial [11]. 
Several studies have demonstrated that the thorax frequently 
harbors undiagnosed pleural disease at the time of the initial 
diagnosis, and that this is likely to affect survival even in cases 
of optimal debulking [12­14]. In addition, a recent study found 
that moderate­to­large pleural effusion on preoperative com­
puted tomography (CT) was associated with a decrease in 
overall survival in patients with stage III or IV EOC after control­
ling for age, preoperative CA­125, surgical stage, ascites, and 
cytoreductive status [15]. Therefore, accurate identification of 
the presence and extent of thoracic disease, including both 
solid metastasis and malignant pleural effusion, is important 
for determining prognosis and selecting appropriate treat­
Fig. 1. Postmenopausal female with stage IV high-grade papillary serous carcinoma. (A) Contrast-enhanced computed tomography (CT) scan 
demonstrates bilateral pleural effusions (white arrows), larger on the right side, at the time of initial diagnosis. Right-sided pleural tap revealed 
positive cytology. Subsequently, bilateral video-assisted thoracic surgery was performed and revealed the presence of microscopic pleural 
metastasis bilaterally. Pleural effusions were treated with talc pleurodesis. (B) Post-treatment follow-up CT images demonstrate residual 
loculated small bilateral effusions (black arrow) and talc-related hyperdensity within the right pleural space (white arrow). (C) Contrast-
enhanced CT scan 4 months after initial diagnosis and neoadjuvant chemotherapy showing residual disease in the abdomen and pelvis (white 
arrow) that was subsequently treated with optimal debulking. (D) Contrast-enhanced CT scan 6 months after optimal debulking showing gross 
pleural metastases (white arrows).Oleg Mironov, et al.
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ment in patients with advanced EOC [15] (Figs. 1 and 2). 
Pleural effusions in ovarian cancer have a higher likelihood 
of malignancy when they are moderate to large in size and as­
sociated with enlarged superior diaphragmatic lymph nodes 
[6]. However, studies on CT indicators of malignant pleural 
effusion have used cytology rather than surgical findings as 
the reference standard [6,16,17]. The accuracy of pleural fluid 
cytologic examination ranges between 40% and 87% [18­
20]. Video­assisted thoracic surgery (VATS) has been shown 
to enable accurate pathological diagnosis and intrathoracic 
resection of pleural metastasis in patients with ovarian cancer 
[21]. In a small retrospective study from our institution, 4/10 
patients (40%) with negative cytological findings had macro­
scopic pleural lesions on VATS [13], and in another such study, 
preoperative CT identified solid pleural disease in only one 
third of patients (2/6) who had macroscopic disease on VATS 
[14]. Therefore, the aims of our study were to compare chest 
CT to VATS, pathology, and cytology findings and determine 
possible CT imaging features that may be predictive of pleural 
malignancy in patients with advanced EOC.
MATERIALS AND METHODS
1. Patients 
Our retrospective, cross­sectional imaging study was com­
pliant with Health Insurance Portability and Accountability 
Act. The institutional review board approved the study and is­
sued a waiver of informed consent. Patients were selected by 
means of a computerized review of institutional gynecologic 
surgery and radiology databases. Consecutive patients with 
primary or recurrent FIGO stage III and IV ovarian cancer who 
underwent CT of the chest up to 30 days before VATS from 
January 1, 1997 through December 31, 2009 were included in 
the study. If a patient had more than one CT study within the 
30 days before VATS, the most recent one was used. A total of 
44 patients (3 with FIGO stage III and 41 with FIGO stage IV) 
were included in the analysis, of whom 41 had primary and 
3 had recurrent disease. Indications for VATS were malignant 
pleural effusion on cytology (12/44), suspected malignant 
nodules or lymph nodes on CT (16/44) or moderate to large 
(defined as occupying 1/3 or more of the lung field on chest 
X­ray) and/or recurrent pleural effusions (16/44).
2. CT examinations
Most of the CT examinations (32/44) were performed with 
intravenous contrast medium, and the slice thickness ranged 
from 5 to 8 mm. For CT examinations performed outside our 
institution, the type of CT scanner and the amount of con­
trast material used were unknown. At our institution, CT was 
performed with various scanners (GE Medical Systems, Mil­
waukee, WI, USA). Our standard CT protocols were tailored to 
the individual scanners. Before October 1, 2000, studies were 
obtained with a conventional non­helical scanner; afterwards 
they were obtained with a helical scanner with one to 64 de­
tector rows. 
For all CT examinations performed at our institution, a dy­
namic power injection of 150 mL of nonionic intravenous 
Fig. 2. Photographs obtained during video-assisted thoracic surgery show (A) white tumor plaques (white arrow) and collapsed lung (black 
arrow), (B) tumor plaques on the pleura (arrow), and (C) biopsy of pleural tumor.Ovarian cancer thoracic metastases: CT vs. VATS
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contrast material was administered at a rate of 2.5 mL/second. 
Time delay to scanning varied with the type of scanner used 
but was determined on the basis of the typical time to portal 
venous phase imaging. All CT studies that were done outside 
our institution were digitized and sent to our enterprise­wide 
picture archiving and communication system. 
3. Image analysis 
Images were retrospectively and independently analyzed 
by two radiologists (SM and ES) who were aware that the 
patients had ovarian cancer but were blinded to the patients’ 
clinical data, prospective CT reports, and pathology findings. 
Both readers were fellowship­trained in body imaging with 8 
years of experience in oncologic imaging. 
For each patient, the radiologists recorded the presence and 
size of pleural effusion. Pleural effusion size was categorized 
based on visual estimation as small (occupying less than 1/3 
of the visualized hemithorax), moderate (1/3 to 2/3 of the 
hemithorax), or large (more than 2/3 of the hemithorax). Pre­
vious work has suggested visual approximation to be about 
85% accurate compared to 3D CT reconstruction [22]. The 
radiologists recorded the presence of pleural nodules, pleural 
thickening (greater than 3 mm), pleural enhancement and 
subdiaphragmatic deposits. They also noted the presence of 
supradiaphragmatic (greater than 5 mm), mediastinal, hilar, 
and retroperitoneal lymphadenopathy. In addition, they esti­
mated the size of ascites and recorded the presence of perito­
neal seeding if present.
4. Reference standard
Results from VATS served as the reference standard. All pro­
cedures were performed at our institution by gynecologic 
oncology and thoracic surgical teams whose members’ expe­
rience ranged from 5 to 25 years. VATS was performed based 
on CT findings. Right­sided VATS was performed in 27 of the 
44 patients, left­sided VATS in 8 and bilateral in 9. The proce­
dure included supradiaphragmatic lymph node dissection if 
indicated (in 12 patients), drainage of effusion (in 35 patients), 
and pleural biopsy of any suspicious areas or of random areas 
if no suspicious areas were identified. A research study assis­
tant (OM) reviewed the intraoperative notes and pathology 
reports retrospectively to determine whether any effusion was 
drained preoperatively or intraoperatively and to record cyto­
pathological and histopathological results (for 9 patients, cy­
tology results were not available either because there was no 
effusion or because macroscopic pleural disease was present 
and thus cytologic evaluation was not completed, as it would 
not have been clinically relevant).
5. Statistical analyses
Differences in age were compared using the Wilcoxon rank­
sum test. Differences in imaging features between benign and 
malignant findings at cytopathology or histopathology were 
evaluated using Fisher’s exact test and Spearman's rank cor­
relation. Kappa statistics along with 95% confidence intervals 
were calculated to assess inter­reader agreement and were 
interpreted as follows: к<0.00, no agreement; 0.00≤к≤0.20, 
slight agreement; 0.21≤к≤0.40, fair agreement; 0.41≤к≤0.60, 
moderate agreement; 0.61≤к≤0.80, substantial agreement; 
and 0.81≤к≤1.0, almost perfect agreement. All p­values less 
than 0.05 were considered statistically significant. All statisti­
cal analyses were performed by using commercially available 
software (SPSS ver. 16.0, SPSS Inc, Chicago, IL, USA; SAS ver. 9.0, 
SAS Institute, Cary, NC, USA). 
RESULTS
1. Patient characteristics 
The patients’ median age was 56 years (range, 40 to 81 
years). The median time from CT to surgery was 7 days (range, 
2 to 30 days). Age did not differ significantly between patients 
with and without solid pleural metastasis (p=0.66) or be­
tween patients with and without malignant pleural effusions 
(p=0.16). 
2. Predicting pleural malignancy
In 26/44 patients (59%), pleural biopsies were positive for 
malignancy. For both readers, the size of left­sided pleural ef­
fusion (rho=-0.39, p=0.01 and rho=-0.37, p=0.01 for readers 
1 and 2, respectively) and the presence of ascites (rho=-0.33, 
p=0.03 and rho=-0.35, p=0.03 for readers 1 and 2, respec­
tively) were the only imaging features associated with malig­
nant pleural involvement on CT, there was no difference in 
the presence of pleural nodules, pleural enhancement, pleural 
thickening, subdiaphragmatic deposits, supradiaphragmatic 
lymphadenopathy, mediastinal lymphadenopathy, retroperi­
toneal lymphadenopathy, hilar lymphadenopathy, supracla­
vicular lymphadenopathy or the presence of peritoneal seed­
ing between patients with and without pleural malignancy at 
biopsy (Tables 1 and 2). 
In 26 (74%) of the 35 patients who had pleural fluid cytology 
available, the results indicated malignant pleural effusion. The 
only features associated with malignant pleural effusion were 
the presence (p=0.03 for both readers) and size (rho=0.34, 
p=0.04 and rho=0.33, p=0.06 for readers 1 and 2, respectively) 
of any right­sided pleural effusion (Tables 1 and 2). Oleg Mironov, et al.
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Table 1. Comparison of CT features in patients with and without pleural malignancy as assessed by reader 1
Malignant disease on biopsy Malignant cells in pleural fluid
Absent Present p-value* Absent Present p-value*
Any moderate or large effusion on CT Present 13 16 0.53 7 22 0.64
Absent 5 10 2 4
Any right-sided effusion on CT Present 9 17 0.36 4 22 0.03
Absent 9 9 5 4
Size of right-sided effusion None 9 9 0.37 5 4 0.01
Small 3 4 1 6
Moderate 2 1 1 2
Large 4 12 2 14
Any left-sided effusion on CT Present  12 10 0.12 7 15 0.43
Absent 6 16 2 11
Size of left-sided effusion None 6 16 0.04 2 11 0.59
Small 2 4 1 5
Moderate 2 4 2 4
Large 8 2 4 6
Pleural nodules on CT Present 2 8 0.16 3 7 0.69
Absent 16 18 6 19
Pleural thickening on CT Present 6 10 0.76 2 11 0.43
Absent 12 16 7 15
Pleural enhancement on CT Present 5 10 0.74 3 12 0.68
Absent 10 13 5 10
Mediastinal adenopathy on CT Present 4 1 0.14 1 2 1
Absent 14 25 8 24
Hilar adenopathy on CT Present 1 0 0.41 1 0 0.26
Absent 17 26 8 26
Supradiaphragmatic adenopathy on CT Present 13 17 0.75 5 18 0.69
Absent 5 9 4 8
Retroperitoneal adenopathy on CT Present 5 6 0.73 3 7 0.67
Absent 12 20 5 19
Supraclavicular adenopathy on CT Present 0 0 N/a 0 0 N/a
Absent 17 26 9 25
Peritoneal seeding on CT Present 17 25 1 9 25 1
Absent 1 1 0 1
Subdiaphragmatic deposits on CT Present 9 19 0.2 7 16 0.45
Absent 9 7 2 10
Size of ascites on CT None 2 4 0.12 0 3 0.10
Small 5 15 2 14
Moderate 4 4 4 3
Large 7 3 3 6
*The p-values are derived from Fisher's exact test and indicate the significance of the association between each computed tomography (CT) 
finding and the presence of malignancy on biopsy or cytology.Ovarian cancer thoracic metastases: CT vs. VATS
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3. Interobserver agreement
Interobserver agreement was substantial (κ=0.78) for pleural 
effusion size and moderate for presence of solid pleural dis­
ease (κ=0.46). Agreement on individual pleural findings varied 
from fair to substantial, with κ values of 0.21 for agreement on 
pleural nodules, 0.48 for agreement on pleural thickening, and 
Table 2. Comparison of CT features in patients with and without pleural malignancy as assessed by reader 2
Malignant disease on biopsy Malignant cells in pleural fluid
Absent Present p-value* Absent Present p-value*
Any moderate or large effusion on CT Present 13 16 0.53 7 22 0.64
Absent 5 10 2 4
Any right-sided effusion on CT Present 9 17 0.36 4 22 0.03
Absent 9 9 5 4
Size of right-sided effusion None 9 9 0.69 5 4 0.16
Small 3 4 1 6
Moderate 2 3 1 4
Large 4 10 2 12
Any left-sided effusion on CT Present 12 10 0.12 7 15 0.43
Absent 6 16 2 11
Size of left-sided effusion None 6 16 0.08 2 11 0.59
Small 2 4 1 5
Moderate 5 5 4 6
Large 5 1 2 4
Pleural nodules on CT Present 7 14 0.37 3 15 0.26
Absent 11 12 6 11
Pleural thickening on CT Present 6 13 0.36 2 15 0.12
Absent 12 13 7 11
Pleural enhancement on CT Present 10 15 1 6 18 0.33
Absent 6 8 3 3
Mediastinal Adenopathy on CT Present 9 8 0.21 2 10 0.44
Absent 8 18 7 15
Hilar adenopathy on CT Present 2 1 0.54 1 1 0.50
Absent 11 22 7 19
Supradiaphragmatic adenopathy on CT Present 13 22 0.45 8 18 0.39
Absent 5 4 1 8
Retroperitoneal adenopathy on CT Present 4 5 1 1 5 1
Absent 13 19 7 19
Supraclavicular adenopathy on CT Present 4 1 0.07 1 2 1
Absent 13 25 8 23
Peritoneal seeding on CT Present 16 22 1 8 25 0.45
Absent 2 4 1 1
Subdiaphragmatic deposits on CT Present 15 19 0.49 6 13 0.63
Absent 3 7 1 7
Size of ascites on CT None 4 8 0.001 1 4 0.646
Small 1 13 2 11
Moderate 8 2 4 6
Large 3 2 1 3
*The p-values are derived from Fisher's exact test and indicate the significance of the association between each computed tomography (CT) 
finding and the presence of malignancy on biopsy or cytology.Oleg Mironov, et al.
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0.61 for agreement on pleural enhancement. Agreement on 
the amount of ascites was fair (κ=0.37).
DISCUSSION
The management of patients with malignant pleural effu­
sions and/or intrathoracic metastasis from primary or recurrent 
advanced EOC is not standardized. The Gynecologic Cancer 
Intergroup Ovarian Cancer Consensus Conference statement, 
2004 [23] and the evidence from randomized controlled tri­
als [11,24] indicate that disease outside the peritoneum pre­
cludes optimal debulking and therefore these patients should 
undergo neoadjuvant chemotherapy followed by cytoreduc­
tive surgery. Still other studies have reported that patients 
with malignant pleural effusions as the only extraperitoneal 
manifestation of the disease have a more favorable prognosis 
than patients with other sites of stage IV disease such as liver 
or distant lymph nodes [25­27]. A study from our institution 
in patients who had optimal cytoreduction showed a worse 
prognosis for those with than for those without malignant 
pleural effusions [12]. Therefore, it is important for patients 
with pleural effusions to be appropriately triaged for intratho­
racic cytoreduction or neoadjuvant chemotherapy depending 
on the feasibility of optimal cytoreduction [13,14,28­30].
In a very recent study of 203 patients with FIGO stage III 
and IV EOC who underwent CT before primary cytoreductive 
surgery at our institution, the presence of moderate­to­large 
pleural effusion on preoperative CT was independently associ­
ated with poorer overall survival (reader 1: hazard ratio [HR], 
2.26, 95% confidence interval [CI], 1.31 to 3.91, p<0.01; reader 
2: HR, 2.25, 95% CI, 1.26 to 4.01, p=0.02) after controlling for 
age, preoperative CA­125, surgical stage, ascites and cytore­
ductive status. Since many patients who had pleural effusions 
did not have the pleural fluid removed and evaluated for ma­
lignant cells, it was unclear if the poor prognosis associated 
with moderate­to­large pleural effusions was due to the size 
of the effusions, the likelihood that they were malignant, the 
possibility that they were associated with bulky intrathoracic 
disease, or a combination of the above. We have previously 
reported that as many as two­thirds of patients with pleural 
effusions have gross intrathoracic disease on VATS [14]. There­
fore, at our institution VATS is now routinely performed in pa­
tients with moderate­to­large pleural effusions.
In our present study the size of pleural effusion and the 
presence of ascites on CT were associated with malignant 
pleural effusion. However, CT features generally considered 
suggestive of solid pleural malignancy such as solid pleural 
nodules, pleural thickening and enhancement were not asso­
ciated with pleural malignancy at biopsy or cytology obtained 
during VATS. Our results agree with those of a prior study of 
15 patients with advanced ovarian cancer, in which video­
assisted thoracoscopy was done to evaluate unilateral or bi­
lateral pleural effusions or (in one patient) to assess the effects 
of neoadjuvant chemotherapy on pleural metastases [31]. 
The study found that preoperative CT had sensitivity of just 
14% and specificity of only 25% for determining pleural status 
when video­assisted thoracoscopy was used as the reference 
standard [31]. 
Several studies have investigated the use of positron emis­
sion tomography (PET) or PET/CT as an alternative imaging 
test for diagnosing pleural metastases in patients with me­
sothelioma and non­small­cell lung cancer; using pathology 
from VATS or cytology obtained from thoracocentesis as the 
reference standard. They found very high accuracy ranging 
from 92% to 97.5% [32­24]. In the primary staging of ovarian 
cancer, Kitajima et al. [35] found that integrated FDG­PET/con­
trast­enhanced CT was more accurate than CT alone. The in­
cremental value of PET/CT in per­lesion accuracy was greater 
in extrapelvic sites, particularly metastatic lymph nodes in the 
abdomen; however, almost all patients (39/40) in the study 
had stage III disease [35]. Further studies are needed to assess 
the potential of PET/CT for evaluating thoracic metastases 
from ovarian cancer. 
Our study had a number of limitations. First, selection bias 
may have affected our results, since patients had VATS be­
cause of suspicion of pleural malignancy based either on CT 
findings or pleural cytology. Optimally, the same study could 
be repeated with patients who routinely undergo VATS re­
gardless of CT findings. Second, we chose an arbitrary period 
of ≤ 30 days between imaging and surgery. However, we re­
viewed only the most recent imaging study for each patient 
so the interval between CT examination and surgery would 
be as short as possible and the analysis of the relationship 
between CT and surgical findings would be valid. Third, we 
combined patients with stage III, stage IV, recurrent disease 
and different histological subtypes. Subgroup analysis was 
not feasible given the limited number of patients who under­
went VATS. Finally, although the size and laterality of pleural 
effusion are unlikely to be affected by scanning technique or 
equipment, we cannot account for the variations in CT tech­
nique and equipment that occurred during the large time­
span of this study. Detection of pleural metastasis could have 
been difficult on digitized images from other institutions, and 
this could account for the fact that inter­reader agreement 
was lower for the presence of solid pleural disease (κ=0.46) 
than for the size of pleural effusion (κ=0.78). Since a number 
of the CT examinations were performed at outside institutions Ovarian cancer thoracic metastases: CT vs. VATS
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it was not possible to apply a computer­assisted method of 
effusion volume estimation, which may be more accurate 
than the visual method that was used in our study.
Our study also had some important advantages compared 
to other published studies. First, to our knowledge, our 
sample size was larger than that of any other published study 
comparing VATS and CT findings of pleural disease in patients 
with advanced primary or recurrent EOC. Second, we relied on 
independent CT readings by two radiologists with substantial 
experience in oncologic imaging rather than consensus evalu­
ation of CT images.
In conclusion, we found that in patients with advanced or 
re  current epithelial ovarian cancer, CT imaging findings gen­
erally considered suggestive of malignant pleural involvement 
such as nodularity, thickening and enhancement of the pleura 
do not predict the presence of pleural malignancy on VATS. 
Therefore, VATS should be considered to evaluate thoracic in­
volvement in ovarian cancer and facilitate appropriate mana­
ge  ment. 
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